Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorKoessler, Thibaud
dc.contributor.authorAlsina Maqueda, Maria
dc.contributor.authorArnold, Dirk
dc.contributor.authorBen-Aharon, Irit
dc.contributor.authorLutz, Manfred
dc.contributor.authorObermannova, Radka
dc.date.accessioned2022-06-15T11:00:45Z
dc.date.available2022-06-15T11:00:45Z
dc.date.issued2021-09
dc.identifier.citationKoessler T, Alsina M, Arnold D, Ben-Aharon I, Lutz MP, Obermannova R, et al. Highlights from ASCO-GI 2021 from EORTC Gastrointestinal tract cancer group. Br J Cancer. 2021 Sep;125:911–919.
dc.identifier.issn1532-1827
dc.identifier.urihttp://hdl.handle.net/11351/7683
dc.descriptionBiliary tract cancer; Colorectal cancer; Drug development
dc.description.abstractLast year the field of immunotherapy was finally introduced to GI oncology, with several changes in clinical practice such as advanced hepatocellular carcinoma or metastatic colorectal MSI-H. At the virtual ASCO-GI symposium 2021, several large trial results have been reported, some leading to a change of practice. Furthermore, during ASCO-GI 2021, results from early phase trials have been presented, some with potential important implications for future treatments. We provide here an overview of these important results and their integration into routine clinical practice.
dc.language.isoeng
dc.publisherSpringer Nature
dc.relation.ispartofseriesBritish Journal of Cancer;125
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectAvaluació de resultats (Assistència sanitària)
dc.subjectImmunoteràpia
dc.subjectAparell digestiu - Càncer - Tractament
dc.subject.meshGastrointestinal Neoplasms
dc.subject.mesh/drug therapy
dc.subject.meshImmunotherapy
dc.subject.meshTreatment Outcome
dc.titleHighlights from ASCO-GI 2021 from EORTC Gastrointestinal tract cancer group
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1038/s41416-021-01474-y
dc.subject.decsneoplasias gastrointestinales
dc.subject.decs/farmacoterapia
dc.subject.decsinmunoterapia
dc.subject.decsresultado del tratamiento
dc.relation.publishversionhttps://doi.org/10.1038/s41416-021-01474-y
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Koessler T] Department of Oncology, Geneva University Hospital, Geneva, Switzerland. Swiss Cancer Center Leman (SCCL), University of Geneva, Lausanne, Switzerland. European Organisation for Research and Treatment of Cancer, Brussel, Belgium. [Alsina M] European Organisation for Research and Treatment of Cancer, Brussel, Belgium. Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Arnold D] European Organisation for Research and Treatment of Cancer, Brussel, Belgium. Department of Oncology, Haematology and Palliative Care, Asklepios Klinik Altona, Asklepios Tumorzentrum Hamburg, Hamburg, Germany. [Ben-Aharon I] European Organisation for Research and Treatment of Cancer, Brussel, Belgium. Division of Oncology, Rambam Health Care Campus, Rappaport Faculty of Medicine, Technion, Haifa, Israel. [Lutz MP] European Organisation for Research and Treatment of Cancer, Brussel, Belgium. Caritasklinikum, Saarbrucken, Germany. [Obermannova R] European Organisation for Research and Treatment of Cancer, Brussel, Belgium. Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute and Faculty of Medicine, Masaryk University, Brno, Czech Republic. Department of Pharmacology, Faculty of Medicine, Masaryk University, Brno, Czech Republic
dc.identifier.pmid34426663
dc.identifier.wos000687550400002
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record